Canaccord Genuity Sticks to Its Buy Rating for Ocuphire Pharma (OCUP)
Canaccord Genuity analyst John Newman maintained a Buy rating on Ocuphire Pharma (OCUP) yesterday and set a price target of $29.00. The company’s shares closed last Tuesday at $4.68, close to its 52-week low of $3.68.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 17.3% and a 45.7% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Allogene Therapeutics.
Ocuphire Pharma has an analyst consensus of Strong Buy, with a price target consensus of $23.50.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.